Kura Oncology (NASDAQ:KURA) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a buy rating in a research report released on Friday morning.

Several other brokerages have also commented on KURA. JMP Securities reiterated a “market outperform” rating and set a $28.00 price target on shares of Kura Oncology in a research note on Thursday, February 6th. UBS Group reduced their target price on Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, March 6th. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Kura Oncology in a research note on Thursday, February 27th. Cantor Fitzgerald upgraded Kura Oncology to a “strong-buy” rating in a research note on Tuesday, March 4th. Finally, Scotiabank lowered their target price on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.50.

Kura Oncology Stock Performance

Shares of KURA stock opened at $5.89 on Friday. The company has a market cap of $475.65 million, a P/E ratio of -2.50 and a beta of 0.83. The firm has a fifty day moving average price of $7.68 and a 200 day moving average price of $11.57. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 12 month low of $5.82 and a 12 month high of $23.48.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analysts’ expectations of $57.96 million. Sell-side analysts predict that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insider Activity

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,729 shares of company stock valued at $92,307 over the last quarter. Corporate insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

Institutional investors and hedge funds have recently made changes to their positions in the stock. Virtus ETF Advisers LLC boosted its holdings in Kura Oncology by 71.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after buying an additional 3,061 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Kura Oncology during the 3rd quarter worth approximately $146,000. Harbor Advisors LLC acquired a new stake in shares of Kura Oncology in the 4th quarter worth approximately $87,000. E Fund Management Co. Ltd. purchased a new position in Kura Oncology in the 4th quarter valued at approximately $90,000. Finally, Corton Capital Inc. acquired a new position in Kura Oncology during the fourth quarter worth $99,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.